SCHEMBL4366847

SCHEMBL4366847

CCN/C(=C/c1ccc(-c2cccc(N(C)C(=O)NCCCc3ccccc3)c2)cc1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAAT3 P53816 1/20 0.39
PLAAT5 Q96KN8 1/20 0.39
PLAAT2 Q9NWW9 1/20 0.39
PLAAT4 Q9UL19 1/20 0.39
FAAH O00519 1/20 0.38
LMNA P02545 4/20 0.38
F10 P00742 1/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 3/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
POLB P06746 3/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP3A4 P08684 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP2C9 P11712 2/20 0.36
JAK2 O60674 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4366850 1.00 PLAAT3 (0.39) PLAAT3PLAAT5PLAAT2PLAAT4FAAH
SCHEMBL4366841 1.00 PLAAT3 (0.39) PLAAT3PLAAT5PLAAT2PLAAT4FAAH
SCHEMBL4220446 0.85 LMNA (0.39) PLAAT3PLAAT5PLAAT2PLAAT4FAAH
SCHEMBL4220448 0.85 LMNA (0.39) PLAAT3PLAAT5PLAAT2PLAAT4FAAH
SCHEMBL4220441 0.85 LMNA (0.39) PLAAT3PLAAT5PLAAT2PLAAT4FAAH
SCHEMBL4229381 0.82 PLAAT3 (0.45) PLAAT3PLAAT5PLAAT2PLAAT4FAAH
SCHEMBL2085502 0.80 FFAR1 (0.50) FAAH
SCHEMBL4209360 0.80 PLAAT3 (0.45) PLAAT3PLAAT5PLAAT2PLAAT4FAAH
SCHEMBL4214815 0.80 PLAAT3 (0.45) PLAAT3PLAAT5PLAAT2PLAAT4FAAH
SCHEMBL4214810 0.80 PLAAT3 (0.45) PLAAT3PLAAT5PLAAT2PLAAT4FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US claimed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US claimed
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA PLAAT3 582/4885PLAAT5 977/4885PLAAT2 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.